Back to top
more

Hologic (HOLX)

(Delayed Data from NSDQ)

$78.76 USD

78.76
1,220,534

-0.53 (-0.67%)

Updated Nov 8, 2024 03:59 PM ET

After-Market: $78.78 +0.02 (0.03%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 26% (65 out of 251)

Industry: Medical - Instruments

Zacks News

Molecular Diagnostics to Aid Hologic's (HOLX) Q3 Earnings

Strength in the Panther system and increasing utilization of Aptima women's health assays will boost Hologic's (HOLX) molecular diagnostics in Q3.

    Hologic's New Panther Fusion System Gets Health Canada Nod

    Hologic's (HOLX) receipt of Health Canada approval for the new Panther Fusion system and Panther Fusion assays, for respiratory virus infections, is expected to boost the top line in the near term.

      Hologic (HOLX) Down 1.6% Since Earnings Report: Can It Rebound?

      Hologic (HOLX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

        Hologic's (HOLX) Q2 Earnings Meet Estimates, Revenues Top

        Solid growth at Hologic's (HOLX) Breast Health and international business drives top line in Q2.

          Medical Product Stock Earnings on May 2: CERN, ABC & More

          Given the solid prospects in the U.S. medical products industry, here we take a peek at four major Medical Product companies scheduled to report results on May 2.

            Can Higher System Sales Drive Cerner's (CERN) Q1 Earnings?

            Cerner's (CERN) Q1 earnings likely to reflect strength in System Sales and lucrative EHR prospects.

              What's in Store for Cardinal Health (CAH) in Q3 Earnings?

              Cardinal Health's (CAH) Pharmaceutical business likely to put up a soft performance in Q3; raised guidance buoys optimism.

                Can BD Medical Drive Becton, Dickinson's (BDX) Q2 Earnings?

                Becton, Dickinson (BDX) likely to gain from core BD Medical segment and strategic buyouts.

                  Can Hologic (HOLX) Diagnostics Growth Recur in Q2 Earnings?

                  A strong Panther system and an increasing utilization of Aptima women's health assays add stimulus to Global growth within Hologic's (HOLX) molecular diagnostics.

                    Can Core Unit Drive Pacific Biosciences' (PACB) Q1 Earnings?

                    Pacific Biosciences gains ground on solid Sequel Growth, while shrinking service revenues raise concern.

                      Can Diagnostic Revenues Drive PerkinElmer (PKI) Q1 Earnings?

                      PerkinElmer (PKI) gains from EUROIMMUN buyout, solid guidance buoys optimism.

                        Can Business Services Aid athenahealth's (ATHN) Q1 Earnings?

                        athenahealth's (ATHN) strong product portfolio, network expansion strategies and unique business model are likely to drive Q1 earnings.

                          4 MedTech Stocks to Keep in Good Books This Earnings Season

                          Considering the ageing population, changing market dynamics, upbeat consumer sentiment and increased business investments, the Medical-Device sector appears to be in pink of health.

                            Hologic's Clarity HD & Intelligent 2D Systems Gain FDA Nod

                            Hologic (HOLX) forges ahead with initiatives to boost the Breast Health business.

                              Should Value Investors Consider Hologic (HOLX) Stock Now?

                              Hologic (HOLX) appears to be a good choice for value investors right now, given its favorable P/E and P/S metrics.

                                Hologic (HOLX) Down 4.5% Since Earnings Report: Can It Rebound?

                                Hologic (HOLX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

                                  Hologic's Alliance With Philips to Boost Breast Health Unit

                                  Hologic (HOLX) is consistently trying to fortify its Breast Health segment.

                                    Here's Why You Must Add Hologic (HOLX) to Your Portfolio Now

                                    Hologic's (HOLX) GYN Surgical business boasts huge future prospects. Also, the recent commercial launch of MyoSure MANUAL device in the United States looks promising.

                                      Hologic Banks on Diagnostics, GYN Surgical Prospects Bright

                                      Hologic (HOLX) stays upbeat about GYN Surgical on the recent commercial launch of MyoSure MANUAL device in the United States.

                                        Hologic (HOLX) Q1 Earnings & Revenues Top, Margins Down

                                        Solid growth at Hologic's (HOLX) Molecular Diagnostics, Breast Health and international business drives the top line in Q1.

                                          CAH vs. HOLX: Which Will Fare Better This Earnings Season?

                                          Here we look at the major factors that are likely to influence the earnings results of a few MedTech bigwigs within the broader Medical universe.

                                            Should You Sell Hologic (HOLX) Before Earnings?

                                            Hologic (HOLX) is seeing encouraging earnings estimate revision activity as of late and carries a favorable rank, positioning the company for a likely beat this season.

                                              Can Molecular Diagnostics Arm Up Hologic (HOLX) Q1 Earnings?

                                              Molecular Diagnostics unit's stellar performance in the first quarter of 2018 is likely to drive Hologic (HOLX) in Q1.

                                                Hologic (HOLX) Up 8% Since Earnings Report: Can It Continue?

                                                Hologic (HOLX) reported earnings more than 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

                                                  Hologic's Panther Fusion Flu AdV/hMPV/RV Assay Wins FDA Nod

                                                  Hologic's (HOLX) recent spree of regulatory approvals for its array of products is encouraging.